Latest News

Deep learning methods (DLMs) have recently been proposed to generate pseudo-CT (pCT) for MRI-based dose planning. This study aims to evaluate and compare DLMs (U-Net and generative adversarial network (GAN)) using various loss functions (L2, single-scale perceptual loss (PL), multiscale PL, weighted multiscale PL), and a patch-based method (PBM). Thirty-nine patients received a VMAT for […]

Accumulating evidence suggest that microRNAs play crucial roles in the development and progression of bladder cancer (BC). Here, we found that miR-212-3p was significantly down-regulated and negatively correlated with nuclear factor IA (NFIA) in human BC tissues. Bioinformatics analysis predicted that NFIA was a target gene of miR-212-3p. Then BC cell lines, T24 and J82 […]

CD81 is a prognostic biomarker for high-grade bladder cancer (BC). In this study, we aimed to determine the functional mechanisms underlying the role of CD81 in BC progression. In two invasive BC cell lines (T24, J82), CD81 expression was suppressed by the transfection of lentiviral vectors including CD81-specific shRNAs, and then the migration and invasion […]

To investigate whether measurement of urinary calprotectin can serve as a biomarker in the diagnosis of primary bladder cancer and to confirm its diagnostic role in determining high grade and stage disease. Urinary calprotectin was measured in spot urine samples from patients with primary bladder cancer and control subjects. To confirm levels in urine, tissue […]

Cancer immunotherapy, particularly a class of antibodies targeting the CTLA4 and PD-1/PD-L1 negative regulators of immune response (collectively called the immune checkpoint), is one of the most promising approaches for cancer treatment and the use of immune checkpoint inhibitors (ICI) has demonstrated remarkable success in several types of cancer. In studies of unselected patient populations, […]

Nivolumab alone and in combination with ipilimumab is approved for the treatment of patients with metastatic renal cell carcinoma (RCC) who received prior vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) and those who are treatment naive, respectively. However, the clinical activity of nivolumab in non-clear cell RCC (nccRCC) is unknown, as these patients […]

Renal cell carcinoma (RCC) is the most common type of kidney malignancy, and the clear-cell subtype represents the majority of RCCs. RCC is a heterogeneous disease in terms of genetic and histological features which determine the behavior of the disease. The von Hippel-Lindau (VHL) is a tumor suppressor gene and mutations of this gene are […]

Martin Gleave: Well good morning. I’d like to thank Silke and Aurelius for the kind invitation to come to this wonderful and unique meeting. I was asked to talk on testosterone measurement, which tests and when, and first I thought, “Oh boy, this is just kind of standard endocrinology. What about all the wonderful molecular […]

Race is a complex topic in any setting, but in healthcare, it is particularly challenging given the influence of social, lifestyle, and structural determinants associated with racial populations. Make no mistake, race matters in cancer outcomes; in prostate cancer, in particular, year after year black men consistently die at nearly 2.5 times the rate of […]

Alicia Morgans: So thank you, everyone. Thank you for being here so early. As we heard, this is a project that’s near and dear to many people’s heart and as we mentioned yesterday and have mentioned I’m sure over time repeatedly, this is really an effort to include the men who are already being treated […]